Search clinical trials for: Epidermal Growth Factor

Total 42026 results

IRCCS San Raffaele
Menarini International Operations Luxembourg SA

Completed

Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

HCM - Hypertrophic Non-Obstructive Cardiomyopathy

Italy
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Spectrum Pharmaceuticals, Inc

Completed

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

EGFR Inhibitor-associated Rash

United States, Canada
Hoffmann-La Roche

Completed

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SCHEARLY)

Breast Cancer

Italy
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN)

Breast Cancer

United States, United Kingdom, France, Italy, Spain, Turkey, Brazil, India
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE)

Breast Neoplasms

Italy, Netherlands, Belgium, United Kingdom, Argentina, Austria, Brazil, China, Ecuador, Estonia, Finland, France, Germany, Greece, Mexico, Peru, Poland, Portugal, Slovenia, Spain, United Arab Emirates, Canada, Hungary, Israel, Sweden, Tu... and more
Hoffmann-La Roche

Completed

A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Breast Cancer

France
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Bayer

Terminated

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms

Spain, Canada, United States, Finland, Austria, Singapore, Czechia, Israel, Korea, Republic of, Netherlands, Taiwan, United Kingdom, Poland, Germany, Hong Kong, Denmark, Switzerland, Ireland, France, Norway
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
First Affiliated Hospital of Harbin Medical University

Unknown

Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

Coronary Artery Disease

China
Cyprus University of Technology

Unknown

Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. (EGFR)

Breast Cancer | Head and Neck Cancer | Lung Cancer | Colon Cancer | Pancreas Cancer | Consent Form

Cyprus
Virginia Commonwealth University
Eli Lilly and Company; Bayer

Terminated

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
AstraZeneca

Completed

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). (ORTUS)

Non-Small Cell Lung Cancer

Russian Federation
AstraZeneca

Completed

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (CONCORDANCE)

NSCLC (Non-small Cell Lung Cancer)

India
Sinocelltech Ltd.

Unknown

SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Unknown

Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Residual Burn Wound

China
Seagen Inc.
Array BioPharma

Completed

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Cancer

Canada, United States
SVS Institute of Dental Sciences

Unknown

RhEGF Incorporated in An Absorbable Collagen Membrane for The Management Of Gingival Recession Defects

Periodontitis

India
University of Alabama at Birmingham

Terminated

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Penile Squamous Cell Carcinoma (PSCC)

United States
Novartis Pharmaceuticals

Completed

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (EVEREXES)

Post Menopausal Breast Cancer

Taiwan, Malaysia, Turkey, Australia, Korea, Republic of, Thailand, Jordan, India, Vietnam, Morocco, Tunisia, Indonesia, South Africa
NYU Langone Health
Bristol-Myers Squibb; Eli Lilly and Company

Completed

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

Neoplasm Metastasis | Colorectal Cancer

United States
Eben Rosenthal
National Cancer Institute (NCI)

Terminated

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

Malignant Glioma | Brain Neoplasm

United States
National Taiwan University Hospital

Completed

The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer

Tumor Progression

Taiwan
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

China
Hoffmann-La Roche

Completed

A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer (HerSCin)

Breast Neoplasms

Germany
Huazhong University of Science and Technology

Unknown

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk

Schizophrenia

China
Hebei Medical University

Unknown

Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

Gastroesophageal Junction Adenocarcinoma

China
Onco Medical Consult GmbH
Eli Lilly and Company; Institut fuer Frauengesundheit

Unknown

Implementing Patients´ Competence in Oral Breast Cancer Therapy (IMPACT)

Advanced Breast Cancer | Metastatic Breast Cancer
Borstkanker Onderzoek Groep
Roche Pharma AG; Teva Pharma

Completed

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (Stop&Go)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Netherlands
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
Hoffmann-La Roche

Terminated

A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Metastatic Breast Cancer

Saudi Arabia
National Cancer Institute (NCI)

Completed

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

Head and Neck Cancer | Laryngeal Cancer | Oral Cancer | Carcinoma, Squamous | Pharyngeal Cancer

United States
National Cancer Institute (NCI)

Terminated

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Carcinoma, Non-Small Cell Lung | Carcinoma, Large Cell

United States
University of Cincinnati
Genentech, Inc.

Withdrawn

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Dana-Farber Cancer Institute
Astellas Pharma Inc

Terminated

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor

United States
National University of Malaysia

Unknown

Endometrial Heparin-binding Epidermal Growth Factor Expression

Gene Abnormality

Malaysia
AstraZeneca
Medpace, Inc.

Completed

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients (RADIANCE)

Non-small Cell Lung Cancer

United States, Canada
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
Hoffmann-La Roche

Completed

A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer (TOXAG)

Gastric Cancer | Gastroesophageal Junction Cancer

Turkey
Hoffmann-La Roche

Completed

Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

Breast Cancer

Saudi Arabia
Hoffmann-La Roche

Completed

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

Breast Cancer

Belgium, Israel
Engeneic Pty Limited
Johns Hopkins University

Unknown

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)

Glioblastoma | Astrocytoma, Grade IV

United States
Hoffmann-La Roche

Completed

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors (KAMELEON)

Bladder Cancer | Pancreas Cancer | Cholangiocellular Carcinoma

Spain, Italy, Netherlands, Slovakia
National Cancer Institute (NCI)

Completed

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Glioblastoma | Brain Cancer | Malignant Glioma | Gliosarcoma

United States
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Johannes Gutenberg University Mainz
Pierre Fabre Pharma GmbH

Completed

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer (VinoMetro)

Metastatic Breast Cancer

Germany

3

Subscribe